Global Food Allergy Diagnostics And Therapeutics Market Size study, by Product (Diagnostics, Therapeutics), by Allergen Source, by End-use, and Regional Forecasts 2022-2032

Global Food Allergy Diagnostics And Therapeutics Market is valued approximately at USD 7.91 billion in 2023 and is expected to grow with a healthy CAGR of more than 8.00% over the forecast period 2024-2032. The food allergy diagnostics and therapeutics landscape has entered a dynamic era shaped by cutting-edge biotechnological advances and a growing global awareness of allergic disorders. Characterized by abnormal immune responses to typically harmless food proteins, food allergies are no longer considered rare pediatric issues but are increasingly prevalent across all age groups, pushing healthcare systems to reevaluate traditional models of allergy identification and management. This transformation is driven by the rising incidence of foodborne hypersensitivities-particularly to peanuts, milk, shellfish, and soy-which has intensified the demand for highly sensitive diagnostic platforms and clinically proven therapeutic interventions that not only detect but also mitigate allergic episodes.

The upward trajectory of the market is bolstered by an ecosystem of converging drivers. The global burden of allergic diseases, the rise of atopic disorders in industrialized nations, and increased access to allergy-focused healthcare are fueling the need for more precise and timely detection methods. Recent developments in multiplex allergen testing, point-of-care diagnostics, and non-invasive testing protocols have reshaped the diagnostic arm of the industry. Simultaneously, the therapeutics segment is witnessing a robust surge with the approval of immunotherapies, monoclonal antibodies, and oral desensitization regimens designed to recalibrate immune responses. Regulatory bodies such as the FDA and EMA are fast-tracking approvals for innovative treatment options, giving pharmaceutical firms an impetus to scale research and pipeline development. Nevertheless, the market faces considerable hurdles, including variability in allergic responses among populations, cost barriers in novel treatment accessibility, and lack of awareness in underdeveloped regions.

A paradigm shift is also occurring in the delivery and accessibility of allergy care through more personalized, end-user focused strategies. While hospitals and specialized allergy clinics remain primary points of contact, the proliferation of home-based test kits, digital diagnostics, and mobile health apps is democratizing access to allergy care. As major players increasingly adopt consumer-centric models, patient engagement has become a focal point-whether through AI-enhanced diagnostic systems or at-home immunotherapy kits. Additionally, strategic collaborations between diagnostic technology providers, research universities, and pharma companies are resulting in breakthroughs that bridge the gap between innovation and affordability. The integration of real-time monitoring tools, wearable biosensors, and machine-learning-based risk profiling is redefining how both diagnostics and therapies are developed, administered, and optimized across geographies.

From a regional perspective, North America holds a dominant share of the Food Allergy Diagnostics And Therapeutics Market due to its high disease prevalence, superior healthcare infrastructure, and strong reimbursement systems for allergy-related treatments. The U.S. has emerged as a breeding ground for innovation, with a substantial number of clinical trials, product approvals, and investments in allergy-focused biotech. Europe trails closely, led by countries like Germany and the UK, which boast of structured allergy surveillance programs and public health policies supporting food safety and allergen labeling. On the other hand, the Asia Pacific region is anticipated to grow at the fastest pace owing to growing urbanization, shifting dietary patterns, and increasing disposable incomes. As the region becomes more exposed to processed foods and Westernized diets, nations such as China, India, and Japan are witnessing a surge in allergy-related cases, spurring demand for robust diagnostic frameworks and scalable therapeutic alternatives.

Major market player included in this report are:

• DBV Technologies
• Aimmune Therapeutics
• Thermo Fisher Scientific Inc.
• ALK-Abello A/S
• Omega Diagnostics Group PLC
• Stallergenes Greer
• AllerGenis
• AllerGen Laboratories
• Genova Diagnostics
• Danaher Corporation
• bioMerieux SA
• Siemens Healthineers
• HYCOR Biomedical
• Nestle Health Science
• Johnson & Johnson Services, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product

• Diagnostics
• Therapeutics

By Allergen Source

• Peanuts
• Milk
• Eggs
• Seafood
• Tree Nuts
• Others

By End-use

• Hospitals
• Diagnostic Laboratories
• Academic Research Institutes
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.